RHY 3.13% 6.2¢ rhythm biosciences limited

Sept '21 Deloitte's review of the National Bowel Cancer Screening Program, page-3

  1. 280 Posts.
    lightbulb Created with Sketch. 95
    @borano


    Review of Phase Four of the National Bowel Cancer Screening Program:

    "In any decision to transition to a new test type, it is important that the test is approved by the
    Therapeutic Goods Administration (as per the guidance in the NBCSP Quality Framework) and a
    cost-effectiveness analysis is performed using reliable estimates of test sensitivity and specificity,
    as compared with the current iFOBT."
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
(20min delay)
Last
6.2¢
Change
-0.002(3.13%)
Mkt cap ! $15.41M
Open High Low Value Volume
6.9¢ 6.9¢ 6.2¢ $9.837K 157.8K

Buyers (Bids)

No. Vol. Price($)
1 49398 6.2¢
 

Sellers (Offers)

Price($) Vol. No.
6.5¢ 29999 1
View Market Depth
Last trade - 13.01pm 26/08/2024 (20 minute delay) ?
RHY (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.